Creative Medical Technology Holdings Achieves Major Clinical Milestone with Positive ADAPT Trial Data and Demonstrates Promising Safety Profile for CELZ-201 (Olastrocel) in Chronic Lower Back Pain Treatment.

Tuesday, Jan 13, 2026 9:16 am ET1min read
CELZ--

Creative Medical Technology Holdings announced positive interim data from its ADAPT clinical trial evaluating CELZ-201 (Olastrocel) for chronic lower back pain. The study showed statistically significant improvements in functional disability and pain, confirming a favorable safety profile. This marks a major inflection point for the company, transitioning CELZ-201 from a clinical program to a strategic asset with significant potential value for patients and shareholders.

Creative Medical Technology Holdings Achieves Major Clinical Milestone with Positive ADAPT Trial Data and Demonstrates Promising Safety Profile for CELZ-201 (Olastrocel) in Chronic Lower Back Pain Treatment.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet